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What is the prognosis of bullous pemphigoid (BP)? The an-
swer is critical to provide meaningful information to our pa-
tients. Unfortunately, the answer is confusing.
The reported mortality of BP is much greater in Europe
than in the US. Mortality 1 year after initiation of therapy
ranges from 19% to 41% in Europe but is only 6%–12% in
the US. This difference is supported by an increasing
number of reports which are remarkably consistent in their
observations, as summarized in Table I. Five European
studies report the 1-year mortality as 19%, 29%, 30%,
40%, 41%, respectively; whereas three reports from the US
report it as less than 6%, 11%, and 12%. In our own un-
published observations on 135 sequential BP patients treat-
ed in a tertiary referral center in New York City during the
past decade, mortality at one year was less than 10%.
Joly and his colleagues in this issue of the JID have of-
fered several possibilities to explain this difference in
outcome. These include differences in treatment, ethnic
differences, age, study size, and patient selection bias.
There is an obvious difference in treatment, as the ma-
jority of patients reported from Europe are hospitalized for
treatment whereas this is the exception in the US. The im-
mediate suspicion that complications of hospitalization is
the cause for the higher mortality in Europe is, however,
refuted by Garcia-Doval and colleagues who in this issue of
the JID indicate that the greatest mortality in their patients
occurred after hospital discharge. Other aspects of treating
BP in Europe and the US are generally similar, and so do not
provide a ready explanation for the differing mortality rates.
Nor does difference in age provide a likely explanation for
the higher mortality reported in Europe. The average age of
patients in two European (Rzany et al, 2002; Garcia-Doval
et al, 2005) and one American study (Colbert et al, 2004) is
identical, i.e., 77 years. Nonetheless, mortality was still three
to four times higher in the European studies.
American studies are generally smaller than those con-
ducted in Europe. However, the consistency of the reports,
i.e., mortality in all European studies, is higher than in all
American studies, and the clear nature of the end-point
(death) suggest the reported differences between European
and American studies are real.
Ethnic differences as the cause for higher mortality in
Europe cannot be formally refuted based on available
data. This is, however, difficult to accept as the studies
conducted in Europe (England, France, Germany, and
Spain) and in the US (Boston, Cincinnati/Detroit, New York
and Milwaukee) both span a wide range of nationalities and
ethnicities.
We suspect the most likely explanation for the differenc-
es in BP mortality between Europe and the US is a patient
selection bias, as initially suggested by Korman (1998). The
published evidence suggests that BP studies in Europe
were conducted in patients who were generally sicker than
those in the US, as was initially argued by Korman (1998).
Whether this is because patients with more severe disease
or comorbidities are not treated in tertiary medical centers
in the US, as suggested by Joly et al (2005), or conversely
because such patients are preferentially referred to tertiary
centers in Europe as we suspect, the results will be the
same—mortality will appear worse in Europe than the US
because it is based on a subset of patients with BP who are
sicker and/or have more comorbidities.
Lastly, the true mortality of BP cannot be discerned
from any of these studies, since none is adjusted for the
expected mortality of age-matched patients with similar
comorbidities.
Table I. Differences in reported mortality for bullous
pemphigoid between Europe and the United States
Study (year) Location
#
patients
Average
age
1-y
mortality
(%)
Europe
Venning (1992) UK 82 74 19
Roujeau et al (1998) France 217 79 41
Joly et al (2002) France 341 81 30
Rzany et al (2002) Germany 369 77 29
Garcia-Doval (2005) Spain 26 77 40
Weighted average 31
United States
Ahmed et al (1977) Boston 36 70 o6
Fivenson (1994) Cincinnati/
Detroit
18 78 12a
New York 135 ? o10
Colbert et al (2004) Milwaukee 37 77 11
Weighted average 10
aAssuming two patients lost to follow-up died.
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